Table 3.
Postoperative nausea and vomiting outcomes
| Phase | Parameter | Control group (n = 55) |
ERAS group (n = 50) |
P value |
|---|---|---|---|---|
| Pre-operation | PONV simple risk assessment, n(%) | 55 (100%) | 50 (100%) | – |
| High-risk individuals, n(%) | 18 (33%) | 20 (40%) | 0.54 | |
| Post-operation | PONV prophylaxis, n(%) | 0 (0%) | 20 (40%) | < 0.01 |
| Complete response | ||||
| POD 1, n(%) | 22 (40%) | 23 (46%) | 0.56 | |
| POD 2, n(%) | 22 (40%) | 31 (62%) | 0.03 | |
| POD 3, n(%) | 29 (53%) | 37 (74%) | 0.02 | |
| Vomiting | ||||
| POD 1, n(%) | 15 (27%) | 9 (18%) | 0.35 | |
| POD 2, n(%) | 12 (22%) | 3 (6%) | 0.02 | |
| POD 3, n(%) | 8 (15%) | 1 (2%) | 0.03 | |
| Nausea score (VAS), POD 1 | 0.33 | |||
| Mild (0–4), n(%) | 24 (44%) | 29 (58%) | ||
| Moderate (5–6), n(%) | 16 (29%) | 11 (22%) | ||
| Severe (7–10), n(%) | 15 (27%) | 10 (20%) | ||
| Nausea score (VAS), POD 2 | 0.01 | |||
| Mild (0–4), n(%) | 25 (45%) | 35 (70%) | ||
| Moderate (5–6), n(%) | 16 (29%) | 11 (22%) | ||
| Severe (7–10), n(%) | 14 (25%) | 4 (8%) | ||
| Nausea score (VAS), POD 3 | 0.02 | |||
| Mild (0–4), n(%) | 33 (60%) | 40 (80%) | ||
| Moderate (5–6), n(%) | 13 (24%) | 9 (18%) | ||
| Severe (7–10), n(%) | 9 (16%) | 1 (2%) | ||
| Antiemetic medication administration | ||||
| POD 1 | ||||
| All antiemetics, no. of requests | 15 (27%) | 21 (42%) | 0.14 | |
| tropisetron, mean mg/user | 2.8 ± 1.2 | 3.0 ± 1.1 | 0.61 | |
| POD 2 | ||||
| All antiemetics, no. of requests | 12 (22%) | 15 (30%) | 0.50 | |
| tropisetron, mean mg/user | 2.5 ± 0.8 | 2.7 ± 1.0 | 0.63 | |
| POD 3 | ||||
| All antiemetics, no. of requests | 8 (15%) | 10 (20%) | 0.60 | |
| tropisetron, mean mg/user | 2.3 ± 0.5 | 2.4 ± 0.7 | 0.60 | |
Data are expressed as number of patients (%). P value indicates the comparison between control group and ERAS group. POD, Postoperative day; PONV, postoperative nausea and vomiting; VAS, Visual Analogue Scale